OverviewSuggest Edit

Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates in two segments: Generics and Specialty. It manufactures and sells a portfolio of injectable products across various therapeutic areas. The Company markets its products to wholesalers, distributors, retail pharmacy chains, group purchasing organizations, government entities, independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers.

TypePublic
Founded1961
HQCanonsburg, US
Websitemylan.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Dec 2018)35,000
Job Openings309
Revenue (FY, 2017)$11.8 B(+54%)
Share Price (May 2019)$19.7

Key People/Management at Mylan

Heather Bresch

Heather Bresch

CEO
Robert Coury

Robert Coury

Non-Executive Director
Robert Cindrich

Robert Cindrich

Non-Executive Director
JoEllen Lyons Dillon

JoEllen Lyons Dillon

Executive Vice-President, Chief Legal Officer
Show more

Mylan Office Locations

Mylan has offices in Canonsburg and Hertfordshire
Canonsburg, US (HQ)
1000 Mylan Boulevard
Hertfordshire, GB
Building 4 Trident Place Mosquito Way
Show all (2)

Mylan Financials and Metrics

Mylan Revenue

Mylan's revenue was reported to be $11.76 b in FY, 2017
USD

Net income (Q1, 2019)

(25.0m)

Market capitalization (22-May-2019)

10.1b

Closing stock price (22-May-2019)

19.7
Mylan's current market capitalization is $10.1 b.
Annual
USDFY, 2013FY, 2014FY, 2016FY, 2017

Revenue

6.9b7.6b11.8b

Revenue growth, %

12%

Cost of goods sold

3.9b4.2b

Gross profit

3.0b3.5b
Quarterly
USDQ2, 2015Q2, 2017Q1, 2019

Revenue

2.4b

Operating expense total

752.0m

Net Income

297.0m(25.0m)
Annual
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

288.02.5k5.9k1.8k163.032.05.1k5.2k28.9k1.2b28.7k

Accounts Receivable

975.0372.02.5k17.4k5.4k5.0k9.3k12.7k2.9b

Inventories

1.7b1.7b2.0b

Current Assets

474.03.4k5.9k2.2k2.6k17.4k10.5k10.2k38.1k41.4k
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019

Cash

587.0m

Accounts Receivable

2.9b3.0b

Inventories

2.6b

PP&E

2.3b2.3b
Annual
USDFY, 2013FY, 2014FY, 2016FY, 2017

Net Income

626.5m933.1m480.0m696.0m

Depreciation and Amortization

516.0m566.6m1.5b

Inventories

(160.0m)(150.0m)

Accounts Payable

137.2m(300.0k)
Quarterly
USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(25.0m)

Depreciation and Amortization

1.5b

Inventories

(183.0m)

Accounts Payable

(45.0m)
Show all financial metrics

Mylan Online and Social Media Presence

Embed Graph

Mylan News and Updates

Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety...

South Africa's Aspen sells Australian prescription portfolio to Mylan

Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy Aspen's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).

Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic Society International Conference

HERTFORDSHIRE, England, and PITTSBURGH, May 18, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced four scientific abstracts from the Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP) development program that will be...

A massive lawsuit just erased $2.5 billion from drug giant Teva's market cap. Here's how much Teva and rival drugmaker Mylan could stand to lose in court.

A major new lawsuit accuses 20 generic drug companies of working together to increase prices on drugs for HIV, cancer and other conditions. It hit many of the companies' stocks hard on Monday, amid widespread US market weakness.  Teva and Mylan, two large generic drugmakers named prominently in th…

Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets

HERTFORDSHIRE, England, and PITTSBURGH, May 10, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg, a generic version of Genentech's Tarceva®. Mylan Pharmaceuticals...

Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

HERTFORDSHIRE, England and PITTSBURGH, May 10, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the 2019 Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Thursday, May 16, 2019 at 10:40 a....
Show more

Mylan Frequently Asked Questions

  • When was Mylan founded?

    Mylan was founded in 1961.

  • Who are Mylan key executives?

    Mylan's key executives are Heather Bresch, Robert Coury and Robert Cindrich.

  • How many employees does Mylan have?

    Mylan has 35,000 employees.

  • Who are Mylan competitors?

    Competitors of Mylan include BioMarin Pharmaceutical, Cipla and Amphastar Pharmaceuticals.

  • Where is Mylan headquarters?

    Mylan headquarters is located at 1000 Mylan Boulevard, Canonsburg.

  • Where are Mylan offices?

    Mylan has offices in Canonsburg and Hertfordshire.

  • How many offices does Mylan have?

    Mylan has 2 offices.